There is evidence that EZH2 is elevated in HCC and promotes proliferation, migration, and invasion of HCC cells, acted as a negative prognostic biomarker associated with immunosuppression, and is associated with sorafenib resistance in HCC [52,53,54,55]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.